GENERICS

June 16, 2017

Generic Drugs in the Pipeline: 2017 Update

An awareness of recent drug approvals, which offer cost-effective treatment options, can help pharmacists facilitate care and improve overall outcomes.
February 16, 2017

Biosimilars in Oncology

WEB EXCLUSIVE: With the patents set to expire for a number of monoclonal antibodies, interest related to cancer biosimilars has expanded.

December 16, 2016

Legal Aspects of Biosimilars

The recent introduction of biosimilars into the U.S. market creates the need for an understanding of FDA and state regulations.

November 17, 2016

The Impact of Generic Medications on Breast Cancer Prevention

Cost savings from generic medications have significantly increased adherence rates, and the impact of these medications on breast cancer survival rates is expected to be significant.
November 17, 2016

Cancer Biosimilars: Regulation Challenges and Clinical Impact

There are currently four FDA-approved biosimilars available in the United States, but only one (Zarxio) has cancer indications.

October 14, 2016

Biosimilars: Current Approvals and Pipeline Agents

To date, only four biosimilars have been approved in the U.S. (Zarxio, Inflectra, Erelzi, Amjevita), although many other agents are under development.

October 14, 2016

Will Pharmacists Fuel Biosimilars?

Pharmacists can build patient confidence about biosimilars, promoting access to more economical treatment.